Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: A phase II study of the Galician Lung Cancer Group (GGCP 013-02)

Anti-Cancer Drugs

Volumn 18, Issue 10, 2007, Pages 1201-1206

  Vázquez, Sergio ^a,g   Huidobro, Gerardo ^b   Amenedo, Margarita ^d   Fírvida, José Luis ^f   León, Luis ^e   Lázaro, Martín ^c   Grande, Carlos ^b   Mel, José Ramón ^a   Ramos, Manuel ^d   Salgado, Mercedes ^f   Casal, Joaquín ^b  

^a HOSPITAL XERAL CALDE   (Spain)

^b Hospital Mexoeiro   (Spain)

^c HOSPITAL XERAL CÍES   (Spain)

^d Regional Cancer Center of Galicia   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f Ourense Hospital Complex   (Spain)

^g Medical Oncology Service   (Spain)

Author keywords

Biweekly; Docetaxel; Non small cell lung cancer; Second line; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 34748848003     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328273bbce     Document Type: Article

References (33)

1. Evans TL, Lynch TJ Jr. Lung cancer. Oncologist 2001; 6:407-414.
2. Bunn PA Jr. Platinums in lung cancer: sufficient or necessary? J Clin Oncol 2005; 23:2882-2883.
3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353.
4. Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004; 9 (Suppl 6):14-24.
5. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003; 21:3016-3024.
6. Douillard JY, Gervais R, Dabouis G, le Groumellec A, d'Arlhac M, Spaeth D, et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol 2005; 16:81-89.
7. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22:254-261.
8. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005; 23:2937-2945.
9. Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 2001; 34 (Suppl 4):S47-S51.
10. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
11. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
12. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001; 6 (Suppl 1):4-7.
13. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3025-3034.
14. Le Chevalier T, Brisgand D, Soria JC, Douillard JY, Pujol JL, Ruffie P, et al. Long-term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001; 6 (Suppl 1):8-11.
15. Miller VA, Krug LM, Ng KK, Pizzo B, Perez W, Heelan RT, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:1346-1350.
16. Bennouna J, Monnier A, Riviere A, Milleron B, Lemarie E, Trillet-Lenoir V, et al. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer 2000; 36:1107-1112.
17. Kourousis C, Androulakis N, Kakolyris S, Souglakos J, Maltezakis G, Metaxaris G, et al. First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine. Cancer 1998; 83:2083-2090.
18. Sanchez JM, Balana C, Font A, Sanchez JJ, Manzano JL, Guillot M, et al. Phase II nonrandomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer 2002; 38:309-315.
19. Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Papadakis E, Bouros D, et al. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 1997; 24 (4 Suppl 14):S14-9-S14-14.
20. Nelli F, Naso G, de Pasquale Ceratti A, Saltarelli R, Dauria G, Lugini A, et al. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial. J Chemother 2004; 16:392-399.
21. Leu KM, Kim KM, Larson M, Schiller JH. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 2001; 34:105-113.
22. Munoz A, Rubio I, Mane JM, Ferreiro J, Fernandez R, Abon G, et al. Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinum-based chemotherapy. Clin Lung Cancer 2002; 4:168-173.
23. Hainsworth JD, Burris HA 3rd, Billings FT 3rd, Bradof JE, Baker M, Greco FA. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced non-small cell lung carcinoma: phase II trials of the Minnie Pearl Cancer Research Network. Cancer 2001; 92:2391-2398.
24. Miller VA, Ng KK, Krug LM, Perez W, Pizzo B, Heelan RT, et al. Phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung carcinoma. Cancer 2000; 88:1045-1050.
25. Vazquez S, Grande C, Amenedo M, Firvida JL, Lazaro M, Alonso G, et al. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anticancer Drugs 2004; 15:489-494.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
27. Hanna N, Shepherd FA, Fossella FV, Pereira JR, de Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.
28. Ramlau R, Gervais R, Krzakowski M, von Pawel J, Kaukel E, Abratt RP, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:2800-2807.
29. Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 2005; 92:15-20.
30. Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-smallcell lung cancer: a randomized phase II trial. Ann Oncol 2005; 16: 294-299.
31. Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 2005; 93:763-769.
32. Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004; 91:482-488.
33. Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 2006; 11:655-665.